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ABSTRACT: The Nucleocapsid protein NCp7 (NC) is a
nucleic acid chaperone responsible for essential steps of the
HIV-1 life cycle and an attractive candidate for drug
development. NC destabilizes nucleic acid structures and
promotes the formation of annealed substrates for HIV-1
reverse transcription elongation. Short helical nucleic acid
segments bordered by bulges and loops, such as the Trans-
Activation Response element (TAR) of HIV-1 and its
complementary sequence (cTAR), are nucleation elements
for helix destabilization by NC and also preferred recognition
sites for threading intercalators. Inspired by these observations,
we have recently demonstrated that 2,6-disubstituted peptidyl-
anthraquinone-conjugates inhibit the chaperone activities of
recombinant NC in vitro, and that inhibition correlates with the stabilization of TAR and cTAR stem-loop structures. We
describe here enhanced NC inhibitory activity by novel conjugates that exhibit longer peptidyl chains ending with a conserved N-
terminal lysine. Their eﬃcient inhibition of TAR/cTAR annealing mediated by NC originates from the combination of at least
three diﬀerent mechanisms, namely, their stabilizing eﬀects on nucleic acids dynamics by threading intercalation, their ability to
target TAR RNA substrate leading to a direct competition with the protein for the same binding sites on TAR, and, ﬁnally, their
eﬀective binding to the NC protein. Our results suggest that these molecules may represent the stepping-stone for the future
development of NC-inhibitors capable of targeting the protein itself and its recognition site in RNA.
■ INTRODUCTION
HIV-1 Nucleocapsid protein (NC) is a small, highly basic
protein of 55 amino acid residues, which mediates essential
replication steps, such as strand transfers during reverse
transcription of viral RNA and genome packaging during virion
assembly.1−3 Its structure is composed of a ﬂexible 11-amino-
acid N-terminus that includes four conserved basic residues
(Lys3, Arg7, Arg10, and Lys11) and a core consisting of two
zinc ﬁnger (ZF) domains.2,4 The fact that ZF motifs are highly
conserved and their mutations render the virus noninfectious
limits the possibility that HIV-1 will be able to generate viable
resistant strains, making NC a promising target for anti-HIV
drug development.3,5−7 The multifaceted activities enacted by
NC originate from its nucleic acid-binding and chaperoning
properties. Its interaction with cognate nucleic acids can induce
transient melting of base-pairing, making previously paired
strands available for reannealing in more thermodynamically
stable structures.8−10 The protein exhibits high aﬃnity for
single-stranded regions: unpaired nucleotides (e.g., bulges or
small loops) in double-stranded stem structures are preferred
nucleation sites for helix destabilization, mediated by speciﬁc
contacts with the ZF domains.11,12 Additionally, numerous
studies have shown that GNG sequences located in the apical
loops of RNA hairpins constitute strong binding sites for the
protein.13−16 These studies have also highlighted the high
ﬂexibility and adaptability of NC to diﬀerent types of nucleic
acid substrates.4,13,15−18
An essential target of NC activity is the Trans-Activation
Response element TAR, a stable stem-bulge-loop domain of the
Long Terminal Repeat (LTR) region of genomic RNA, which
is also required for Tat-mediated transcription.19 Annealing of
TAR to reverse-transcribed complementary DNA (cTAR) is an
obligatory step of reverse transcription, which is mediated by
NC.1,20 Based on this premise, we hypothesized that small
molecules capable of stabilizing these nucleic acid structures
could interfere with the melting and annealing activities of NC,
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and we proved that disubstituted anthraquinone derivatives
acting as threading intercalators were eﬃcient NC inhibitors in
vitro.21 These compounds consist of a planar nucleus with the
positively charged side chain substituents at the opposite sides
of the ring system, such that one of the two substituents threads
through the base pairs in the duplex to locate each chain in the
nucleic acid grooves in the ﬁnal intercalation complex.22 The
observed NC inhibition of disubstituted anthraquinones was
enhanced when a basic amino acid (e.g., lysine, AA2) was the
terminal anchor conjugated through a βAla spacer (AA1) to the
2 and 6 position of the ring system (compound 1, Figure 1);21
preliminary experiments indicated in fact that NC inhibition
was achieved also when the lysyl-peptidyl-chains were longer
(compound 6, Figure 1).23
The aim of this work is to investigate the molecular
mechanism(s) of lysyl-peptidyl-anthraquinones action in order
to optimize NC inhibition. The present paper examines, in fact,
a series of selected 2,6-disubstituted-anthraquinones with side
chains diﬀerent in length and composition, but characterized by
an invariable N-terminal lysine (AA3) conjugated to the planar
nucleus through amino acidic linkers (AA1, AA2) (compounds
3−6 in Figure 1, detailed in Supporting Information Figure S1).
In previous studies focusing on G-quadruplex oligonucleotides,
the same conjugates were described to exhibit preferential
recognition of noncanonical conformations of nucleic acids
over double stranded DNA.24 However, their binding to
dynamic DNA or RNA structures was not analyzed. Given their
structure and the mentioned preliminary results, we veriﬁed
whether these compounds have the potential to inhibit NC as
demonstrated for 1.21 Relative to our positive control 1, they
place the electrostatic component of the side-chain in a more
distal position from the intercalation moiety. Compound 2,
lacking the amino side chain, was used as a negative control.
The inhibitory properties of these bioconjugates were tested
in vitro by the concerted application of (i) ﬂuorescence
quenching assay (FQA), (ii) nucleocapsid annealing-mediated
electrophoresis (NAME) assays, (iii) RNA footprinting, and
(iv) direct infusion mass spectrometric (MS) analysis.
■ RESULTS AND DISCUSSION
Lysyl-Peptidyl-Anthraquinones Inhibit NC-Mediated
Helix Destabilization of Folded TAR and cTAR. A
framework for understanding the in vitro eﬀects of the selected
anthraquinone conjugates on the NC-induced destabilization of
TAR and cTAR structure was obtained by performing high
throughput screening (HTS) experiments.21,25 The apical
portion of viral TAR domain was reproduced by a 29-nt
RNA construct (that we called TAR) which combines a double-
stranded stem with single-stranded loop and bulge regions. A
complementary deoxy-oligonucleotide sequence (cTAR) was
employed to mimic the DNA counterpart. Each construct was
properly double-labeled as previously described.21,26 NC can
induce melting of the lower half of the oligonucleotide stem,
which increases the distance between ﬂuorophore and
quencher manifesting an increase of ﬂuorescence. The
inhibition of NC’s helix destabilizing activity results in a
quenching of ﬂuorescence due to the proximity of the stem
ends. After preliminary controls to ensure the absence of direct
quenching activity by the compounds under investigation, their
ability to inhibit stem melting was evaluated in the presence of
recombinant full-length HIV-1 NC. Progressive increases of
lysyl-peptidyl-anthraquinone amount allowed us to determine
the concentration that induced 50% reduction of the stem-
destabilizing activity of NC (i.e., IC50)
21,25 on TAR and cTAR
(Table 1).
The results summarized in Table 1 clearly show that, with
the exception of the inactive compound 2, all tested lysyl−
peptidyl conjugates inhibited NC-induced melting of TAR and
of cTAR at micromolar concentrations. For 3−6, inhibition of
stem-melting was achieved at slightly lower concentrations
(IC50’s) when cTAR rather than TAR was considered. This
observation is consistent with the typically greater destabilizing
eﬀects of NC on the cTAR’s stem previously reported by other
authors.27 Among the lysyl-peptidyl-anthraquinones, com-
pound 4 provided the highest level of inhibition in the series
toward cTAR. Notably, compound 6 emerged from our analysis
as the most potent NC inhibitor of the series toward TAR and,
interestingly, it was more active than 1 in inhibiting NC-
mediated stem melting activity on both TAR and cTAR
constructs.
Lysyl-Peptidyl-Anthraquinones Inhibit NC-Mediated
Annealing of TAR to cTAR. In addition to the eﬀects of lysyl-
Figure 1. Schematic structures of peptidyl−anthraquinone conjugates included in the study.
Table 1. Inhibition of NC-Induced Helix Destabilization
(Melting) by Peptidyl-Anthraquinones
1Data are averages ± SEM of three independent experiments.21
2Reported in ref 21.
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peptidyl-anthraquinones 3−6 on the stem-melting activity of
NC, we investigated the eﬀects on the strands-annealing
properties by using the recently described nucleocapsid
annealing mediated electrophoresis (NAME) assay.23 This
assay is based on the ability of NC or of its truncated form
(NC12−55 peptide) to mediate TAR/cTAR annealing, after
eﬃcient melting of the substrates’ stems. The annealing process
involves the speciﬁc interaction between apical loops of the two
complementary sequences and proceeds through several
intermediate steps to form the hybrid extended duplex TAR/
cTAR.28 The shorter NC12−55 peptide lacks the basic N-
terminal tail that is credited for the nonspeciﬁc nucleic binding
properties, but retains both ZF motifs involved in the
chaperoning activities. We tested both the protein and the
peptide in the NAME assay: unlabeled prefolded TAR and
cTAR were mixed with either full-length NC or NC12−55
peptide in the presence of increasing ligand concentrations,23
and the outcome of the annealing activity was observed by
monitoring the formation of annealed TAR/cTAR hetero-
duplex by nondenaturing gel electrophoresis (see Experimental
Section).
Anthraquinone derivatives 1−6 were tested in triplicate and a
representative example of NAME assay obtained in the
presence of 5 is reported in Figure S2 (Supporting
Information). The progressive increase of peptidyl−anthraqui-
none conjugate concentration induced a decrease of the
intensity of the band corresponding to the extended TAR/
cTAR heteroduplex with a concomitant increase of the bands of
free TAR and cTAR. The formation of intermediate complexes
was also reduced in unison with the inhibition of extended
heteroduplex, an outcome consistently observed in assays that
used either full-length NC or NC12−55 peptide. The formation
of the extended heteroduplex was quantiﬁed as a function of
inhibitor concentration in three independent analyses. The
calculated IC50 for the inhibition of the annealing activity
promoted by full-length NC and NC12−55 peptide are reported
in Table 2.
The peptidyl-anthraquinones 3−6 proved to be strong
annealing inhibitors, with potency similar to that of
acutissimins, natural products that bind and inhibit NC.26
Annealing inhibition was achieved at lower concentrations in
experiments with the truncated NC12−55 peptide, but the
relative ranking of potency in the presence of full-length NC
was comparable. Considering that truncation can limit the
aﬃnity of binding, but not the chaperoning activity, suggests a
direct competition between the protein and the compounds for
the same binding sites onto the nucleic acid structures. As
expected, compound 2 lacking lysine was the least active in
both type of tests. Compounds 3−5 are clearly more potent
annealing inhibitors than 1, which contradicts the results of
NC-induced melting experiments with TAR RNA (Table 1). It
is also interesting to note that 6 was the most active inhibitor in
the annealing test as well as in the NC-mediated stem melting
activity toward TAR. Finally, we could observe that with the
full-length protein the shorter G-spacer (AA1 of the peptidyl
chain in 5 and 6) is slightly better suitable than βAla to achieve
NC inhibition.
Lysyl-Peptidyl-Anthraquinones Inhibit TAR-Tat Com-
plex Formation. NC is not the only viral protein binding
TAR: the HIV-1 trans-activator of transcription (Tat) has been
recently described as a nucleic acids annealer, and shown to
support NC in annealing reactions during reverse tran-
scription.29,30 Tat, in addition, is crucially required for eﬃcient
transcription of the integrated HIV viral genome31,32 and its
biological activity relies on its speciﬁc binding to TAR.33,34 We
therefore tested the ability of 1−6 to impair the complex
formation between TAR RNA and a Tat peptide replicating the
minimal amino acid sequence (48−57) necessary for TAR
binding.35,36 The protocol previously reported37,38 is based on
the use of TAR labeled with a quencher moiety and of Tat
labeled with a ﬂuorescent dye (see Experimental Section). The
ﬂuorophore emits eﬃciently when the peptide is free in
solution, but its emission dramatically decreases when the
complex is formed. Interference on Tat/TAR complex
formation by the peptidyl−anthraquinone conjugate is clearly
seen by the increase in ﬂuorescence signal compared to what
was observed in the peptide/nucleic acid titration curve, in the
absence of inhibitors. These measures allowed us to determine
the inhibition constants for each compound, as reported in
Table 3.
Our results indicate that Tat/TAR complex formation was
strongly inhibited by lysyl-peptidyl-anthraquinone. It is
interesting to note that compounds 3−6 are clearly more
potent Tat/TAR inhibitors than 1 (Table 3), as well as more
potent NC-mediated annealing inhibitors than 1 as observed
above (Table 2). In light of this dual activity, and of the fact
that both NC and Tat proteins share TAR as substrate, our
working hypothesis is that the in vitro activity of these longer
conjugates relies on strongly targeting TAR RNA and that this
eﬀect is relevant for NC inhibition.
Table 2. Peptidyl-Anthraquinones Inhibition of NC-
Mediated Annealing
1Values are the mean ± SEM of three experiments performed in
triplicate. 2Reported in ref 21.
Table 3. Inhibition of Tat/TAR Complex Formation by
Peptidyl-Anthraquinones
compound − (side chain) Kia (μM)
1 − (βAla-K) 0.21 ± 0.01
2 − (βAla-A) not active
3 − (βAla-A-K) 0.09 ± 0.01
4 − (βAla-G-K) 0.08 ± 0.01
5 − (G-A-K) 0.06 ± 0.01
6 − (G-G-K) 0.08 ± 0.02
aValues are the mean ± SEM of three experiments performed in
triplicate.
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Lysyl-Peptidyl-Anthraquinones Stabilize Stem-Loop
Structured Nucleic Acids. The peptidyl−anthraquinone
conjugate 1 acting as a threading intercalator was able to
stabilize the stem-loop structures of TAR and cTAR, and its
NC inhibition was related to the stabilization of these dynamic
structures.21 We therefore decided to investigate the ability of
3−6 to bind and stabilize TAR and cTAR stem-loop structures
by performing ﬂuorescence quenching assay (FQA). Folded
TAR and cTAR were analyzed in the absence/presence of
compound, and the intercalation into nucleic acids was
evidenced by an increase in melting temperature (Tm). The
results obtained from samples containing 1 μM of nucleic acid
substrate and 10 μM of each compound are summarized in
Figure 2.
A marked increase of melting temperature of both RNA and
DNA constructs was observed in the presence of compounds
3−6, consistent with the hypothesis that these anthraquinones
induce an eﬃcient stabilization of nucleic acid double-helices.
As demonstrated for 1, the bioconjugates 3−6 eﬃciently
stabilize TAR and cTAR substrates by intercalation into
double-stranded nucleic acids and/or by stacking in the
bulge/loop regions, as expected by threading intercalators.21,39
All tested compounds showed, not surprisingly, lower
stabilization of the RNA compared to DNA construct,
consistent with eﬃcient intercalation of the planar anthraqui-
none ring into DNA, and in accordance with the lower
inhibition of NC-induced stem melting on TAR over cTAR
(Table 1). Stabilization was enhanced by the presence of lysine,
as demonstrated by the lower ΔTm induced by compound 2
lacking the charged side-chains, conﬁrming the inﬂuence of
electrostatic interactions in nucleic acid binding. It is interesting
to note that in the thermal melting experiment the ligands of
the G-spacer series (5 and 6) stabilize the TAR construct
slightly better than the compounds (3−4) bearing the βAla
linker, suggesting the possibility to modulate TAR recognition
by ﬁne-tuning the peptidyl chain substituents. Moreover, the
enhanced TAR stabilization by 5 and 6 correlates with their
higher NC-mediated annealing inhibition (Table 2) and with
their better eﬀects on the Tat/TAR complex formation (Table
3).
These considerations prompted us to further analyze their
TAR binding mode to prove our working hypothesis that the
longer lysyl-bioconjugates eﬃciently target TAR RNA.
Lysyl-Peptidyl-Anthraquinones Binding Sites on TAR
RNA. In order to investigate the location of putative binding
sites of lysyl-peptidyl-anthraquinones on TAR, we set out
footprinting experiments carried out treating radioactively
labeled RNA, in the absence/presence of 5, with ribonucleases
having diﬀerent speciﬁcities (Figure 2). We employed RNase
T1 that cleaves single-stranded G; RNase A that hydrolyzes
single-stranded C and U; and RNase V1 that preferentially
attacks base-paired nucleotides.40 Cleavage mixtures produced
by increasing concentrations of enzyme were analyzed by
denaturing gel electrophoresis. Footprinting data obtained in
the absence/presence of compound 5 are reported in Figure 3.
In the absence of ligand, RNase T1 digestion produced
preferential cleavage at G16 and, to a minor extent, G17 and
G18 of the apical loop, which is consistent with their exposed
placement in a single-stranded region. In contrast, the presence
of ligand induced signiﬁcant inhibition of nuclease activity in
the same RNA region (see red box of Figure 3a, G16, G17, and
G18 in the RNase T1 lanes). Comparable protection eﬀects
were also observed for the apical U15 upon treatment with
RNase A (green box in Figure 3a, U15 in the RNase A lanes).
At the same time, digestion by RNase V1 provided valuable
insights into possible interactions involving base-paired
nucleotides in the stem regions of the construct. Owing to its
placement in a double-stranded region near the bulge, the G10
position was readily cleaved in the absence of compound 5, but
eﬀectively protected by ligand binding (blue box in Figure 3a).
A similar behavior was observed for the double-stranded A6
nucleotide lining the bulge (blue box in Figure 3a). The actual
bulge nucleotides (i.e., U9, C8, and U7) were readily attacked
by RNase A, but protected in the presence of 5 (green box in
Figure 3a).
Inhibition of G10 and A6 hydrolysis was consistent with
threading intercalation of the anthraquinone nucleus between
the base pairs comprising these nucleotides and the adjacent
ones in the surrounding stems (see cartoon in Figure 3b).
Therefore, protection of unpaired bulge nucleotides (UCU,
positions 7−9) could be explained by possible interactions with
charged side-chains projected from the intercalated ligand.
Interestingly, the sites protected by compound 5 correspond
very well with the speciﬁc sites of destabilization of TAR RNA
by NC, recently identiﬁed by McCauley et al.41 The apical loop
nucleotides G16, G17, G18, and U15 are placed farther away
from the double-stranded stem of TAR and may not be within
the reach of the side-chains of the intercalated ligand.
Intercalators are, however, capable of binding also to single-
stranded regions by establishing stacking interactions with
exposed unpaired nucleobases.42 This possibility could help
explain the observed protection eﬀects that we summarized in
Figure 3b. The footprinting experiments with 5 on TAR RNA
clearly identiﬁed two preferential binding sites located in the
apical loop and bulge regions. It is striking to note that the
unpaired bulge domain is the binding site of Tat protein on
TAR,43,44 while the weakly base-paired G bases on TAR
hairpin41 and the G-rich loop that cap TAR stem constitute the
preferred nucleation sites of NC.13,14,16 These results raised the
possibility that such ligands may interfere directly with NC
Figure 2. Variations of melting temperature (ΔTm) manifested by
TAR (blue) and cTAR (red) in the presence of peptidyl-
anthraquinones. Side-chain sequences are in parentheses. Reported
values are the mean ± standard error of the mean (SEM) of triplicate
experiments performed on samples containing 1 μM of nucleic acid
and 10 μM of ligand. Reference Tm values for TAR and cTAR in the
absence of ligand are 69.3 and 53.8 °C, respectively.
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binding to TAR, representing a valid inhibition mechanism in
addition to the dynamic structures stabilization.
Binding Modes of Lysyl-Peptidyl-Anthraquinones to
TAR. To better analyze the binding to TAR, we were
particularly interested in determining unambiguously the
stoichiometry of the binding interactions established by the
peptidyl−anthraquinone conjugates with the RNA construct
employed as target. Ligand interactions were thus monitored by
using electrospray ionization mass spectrometry (ESI-MS)
under typical conditions that enable the detection of intact
noncovalent complexes of oligonucleotides.45−47 Control
experiments were initially completed to verify the experimental
mass of TAR (i.e., 9286.2 u), which matched the monoisotopic
value calculated from the sequence (i.e., 9286.3 Da).
Subsequently, we analyzed solutions containing 1 μM of TAR
in the presence of increasing ligand concentrations (i.e., up to a
10:1 lysyl-peptidyl-anthraquinone:oligo molar ratio). Figure 4
shows representative ESI-MS spectra obtained in negative ion
mode. Only the regions containing the 7- charge state are
displayed for TAR samples in the presence of 1, 5, and 6. The
spectra contained signals corresponding to free construct, as
well as stable complexes with diﬀerent stoichiometries,
conﬁrming the ability of ESI-MS to preserve the noncovalent
interactions established by the lysyl-peptidyl-anthraquinones.
Table S1 (Supporting Information) summarizes the exper-
imental and calculated masses for all the species detected in
these experiments.
The results showed that all compounds bearing lysine as
terminal amino acid (1, 3−6), bound TAR with stoichiometries
up to 2:1 = compound:RNA (Table S1), which revealed the
presence of multiple binding sites. Only the 1:1 complex was
detected for compound 2 lacking lysine (Table S1). The fact
that free and bound forms of the construct shared the same
charge state allowed us to use signal intensities to infer valuable
information on their actual partitioning at equilibrium.45,48 In
general, when a receptor with multiple sites is considered, the
presence of a predominant site with much greater aﬃnity
translates in the saturation of such site before others are
Figure 3. Nuclease footprinting analysis of TAR in the absence/presence of compound 5. (a) Sequencing gel obtained from samples containing 0.6
μM of radiolabeled TAR without/with 300 μM of 5, which were treated with RNase T1 (red), RNase V1 (blue), and RNase A (green). RNA was
digested with three sequential 10-fold dilutions of each ribonuclease starting from RNase T1 1 U/μL, RNase V1 0.1 U/μL, and RNase A 1 μg/mL.
The analysis was completed by denaturing gel electrophoresis (Polyacrylamide 20%, 7 M urea, TBE buﬀer) carried out at 95 W for ∼1.5 h. Control
samples that were not treated with RNases are indicated with “nt”. A control submitted to alkaline hydrolysis by heating for 5 min is indicated with
“ALK”. (b) Summary of footprinting results. The cloudlike shapes identify nucleotides protected by the lysyl-peptidyl-anthraquinone 5.
Figure 4. Representative ESI-MS spectra of samples obtained by
mixing 1 μM of TAR with 10 μM of lysyl-peptidyl-anthraquinone 1, 5,
or 6 in 150 mM ammonium acetate (see Experimental Section for
conditions). Panel a was obtained from a sample containing 1-(βAla-
K) and TAR, panel b from 5-(G-A-K) and TAR, and panel c from 6-
(G-G-K) and TAR. The stoichiometry of bound species is reported in
each spectrum. Lower intensity signals near free/bound species consist
of typical sodium and ammonium adducts.
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occupied by ligand, which can lead to the accumulation of a 1:1
complex and disappearance of free unbound receptor before
any 2:1 complex is detected. In Figure 4a, for example, this
possibility was clearly incompatible with the simultaneous
detection of both free TAR (i.e., [TAR - 7H]7−) and its 2:1
complex with species 5 (i.e., [TAR·2(5) - 7H]7−). When
binding is cooperative, occupation of the ﬁrst site translates into
a signiﬁcant increase of the probability of binding to the second
one, which manifests in the absence of accumulation of 1:1
complex and simultaneous detection of both free and 2:1
complex. The pattern observed in Figure 4a did not support
signiﬁcant cooperativity, but was instead consistent with the
presence of two independent binding sites with comparable
aﬃnities. Similar binding modes were detected for all the TAR
complexes observed in the study. Interestingly, these data are in
accordance with the footprinting analysis that revealed two
preferential binding sites of 5 on TAR (Figure 3). Hence, a
direct competition between the protein and compounds for the
same binding sites on TAR structure constitutes a valid
inhibition mechanism for lysyl-peptidyl-anthraquinones, but is
not suﬃcient to resolve the observed diﬀerences in NC
annealing inhibitory activity observed for 5 and 6 compared to
1 (Table 2).
Direct Binding of Lysyl-Peptidyl-Anthraquinones to
NC Protein. The possibility that ligands may bind directly to
NC could represent a valid explanation for the observed
discrepancy. In order to test this hypothesis, we probed the
ability of compounds 1, 5, and 6 to bind full-length NC. The
outcome was monitored by ESI-MS determinations under
conditions that have been proven to enable the detection of
intact zinc-bound NC.49 Accordingly, the analysis of protein
sample in the absence of ligand aﬀorded a mass of 6488.905 Da,
which matched very closely the monoisotopic value of
6488.906 Da calculated from the sequence and including two
Zn(II) ions. Representative spectra obtained in the presence of
selected lysyl-peptidyl-anthraquinones are shown in Figure 5,
while the observed masses are reported in Table S4
(Supporting Information).
The results clearly show that the selected ligands are capable
of binding to full-length NC to form stable 1:1 complexes.
Given that these species were detected with the same charge
state, an examination of their signal intensities allowed us to
assume that compounds 5 and 6 do bind NC with higher
aﬃnity compared to 1.45,48 This result matched very closely the
data from the NAME assays, since 5 and 6 resulted in stronger
NC inhibitors than 1 (Table 2). These observations revealed a
direct correlation between side-chain composition, NC-binding,
and inhibition. This is substantiated by the fact that the species
with side-chains of extensive (5 and 6) and limited (1) size
were at the opposite ends of the putative scale of NC binding
and NC inhibitory activities. This suggests that the shorter
derivative 1 could be better described as a nucleic acid
intercalator, whose NC inhibition is due to the ability of
stabilizing the nucleic acid substrates and to the competition for
NC binding sites on TAR. The longer conjugates, placing lysine
more distal from the planar moiety instead, include direct
protein binding as an additional mechanism for achieving
eﬀective NC inhibition.
■ CONCLUSIONS
Our study clearly demonstrates that lysyl-peptidyl-anthraqui-
none conjugates are strong in vitro inhibitors of HIV-1 NC
activities. In analogy with 1, compounds 3−6 bind to and
stabilize eﬃciently TAR and cTAR structures, with a better
recognition of DNA over RNA construct. The results with NC
showed that derivatives 3−6 display inhibition of the NC-
mediated TAR and cTAR helix destabilization comparable to
the reference 1; however, surprisingly, they show higher
potency than 1 in inhibiting NC-mediated annealing activity.
Interestingly, conjugates 3−6 are also more potent inhibitors of
the Tat/TAR complex formation, displaying the same trend of
activity identiﬁed for the NC-annealing inhibition. The slightly
greater stabilization eﬀect on TAR RNA exhibited by
compounds 5 and 6, compared to the other conjugates,
correlates with their slightly enhanced inhibition of both the
NC-mediated annealing and the Tat/TAR complex formation,
conﬁrming the importance of TAR RNA in the elucidation of
lysyl-peptidyl-anthraquinones inhibition mechanism. These
considerations and the fact that both NC and Tat proteins
share TAR RNA as nucleic acid substrate, highlight the critical
role of TAR in the inhibition mechanism of the tested
conjugates. For this reason, we further analyzed their
interactions with TAR RNA. An important clue was provided
by RNA footprinting analysis, which identiﬁed apical loop and
bulge regions as putative ligand sites onto TAR. These regions
correspond respectively to the typical single-stranded structures
preferred by NC binding13,15 and to the binding site of Tat on
TAR.43,44 Therefore, it is very likely that ligands compete with
protein binding to the RNA substrate, a hypothesis supported
by the recent data on NC binding to TAR RNA.41 We further
analyzed the direct binding of lysyl-peptidyl-anthraquinones
with TAR construct by ESI-MS and identiﬁed the coexistence
of two independent binding sites on TAR sharing similar
aﬃnities and negligible cooperativity, which conﬁrm foot-
printing data. Finally, our study demonstrates that longer
conjugates can bind directly to NC, which advances protein
binding as another additional component of their overall
inhibitory activity. The structural determinants of the aﬃnity of
these derivatives toward NC are not well understood and will
require further investigation.
Figure 5. Representative ESI-MS spectra of NC samples in the
presence of (a) 1-(βAla-K), (b) 5-(G-A-K), and (c) 6-(G-G-K). Each
analysis was completed in positive ion mode on solutions containing 2
μM of NC protein and 40 μM of ligand (see Experimental Section).
The observed binding stoichiometries are indicated in the ﬁgure.
Weaker signals near the main peak are typical sodium and ammonium
adducts. Only the region containing the complex is reported for clarity.
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Hence, we demonstrate that at least three combined
mechanisms are contributing simultaneously to the overall
NC inhibitory activity of this class of conjugates. The inhibitory
activity of lysyl-peptidyl-anthraquinone conjugates on NC and
Tat opens the possibility to consider them as multitarget
inhibitors, able to interfere not only with NC-mediated
reactions during reverse transcription, but also with the Tat-
mediated transcription process, resulting eventually in the
impairment of the viral replicative cycle at multiple steps.
Therefore, our study indicates that the development of peptidyl
bioconjugates for targeting RNA stem-loop structures alone, or
in the context of their biologically relevant complexes, is
certainly a viable strategy in the search for new molecules
against druggable viral targets.
■ EXPERIMENTAL SECTION
Materials. Anthraquinones were synthesized as reported.24
All oligonucleotides were synthesized by Metabion Interna-
tional AG (Martinsried, Germany) and stored at −20 °C in 10
mM Tris-HCl, pH 7.5. Dilutions were made in DEPC-treated
water (Ambion). TAR is the 29-mer RNA sequence 5′-
GGCAGAUCUGAGCCUGGGAGCUCUCUGCC-3′ and
cTAR is its DNA complementary sequence 5′-GGCAGAG-
AGCTCCCAGGCTCAGATCTGCC-3′. When speciﬁed, TAR
and cTAR were labeled at 5′- and 3′-ends, respectively, by the
ﬂuorophore 5-carboxyﬂuorescein (FAM) and the dark
quencher 4-(4′-dimethylaminophenylazo)benzoic acid (Dabc-
yl).
The full-length recombinant NC protein was obtained as
reported.47 The protein concentration was determined on a
UV−vis Spectrophotometer Lambda 20, PerkinElmer, using an
extinction coeﬃcient at 280 nm of 6410 M−1 cm−1.
Solid-Phase Synthesis of NC12−55 Peptide. The NC12−55
peptide was synthesized using a fully automated peptide
synthesizer at room temperature on 100 mg of Nova Syn TGA
Asn(Trt) resin (loading 0.20 mmol/g). N-Fmoc deprotection
was performed in two stages using piperidine-DMF 40% for 2
min followed by piperidine-DMF 20% for 10 min. The resin
was then washed with DMF. Coupling reactions were
performed using N-Fmoc amino acids (5 equiv), TBTU (5
equiv) in DMF, and DIPEA (10 equiv) in NMP. All couplings
were performed for 20 min. After each coupling the resin was
washed with DMF (4×). At the end the resin was washed with
DCM (3×) and dried. Peptide cleavage from the resin and
deprotection of the amino acids side chains were carried out for
3 h at room temperature with Reagent K (TFA 94%, anisole
2%, Phenol 2%, EDT 2%, H2O 2%). The crude products were
precipitated with diethyl ether, collected by centrifugation,
dissolved in H2O, and lyophilized. The products were
characterized by RP-HPLC ESI-MS (Waters Alliance 2695
apparatus equipped with a diode array detector) using a
Phenomenex Kinetex C-18 column 2.6 μm (100 × 3.0 mm) 0.6
mL/min. The solvent systems used were: A (0.1% TFA in H2O
Milli-Q) and B (0.1% TFA in CH3CN); with diﬀerent gradients
at 0.6 mL/min in 5 min. The NC12−55 peptide was resuspended
in Tris-HCl 10 mM pH = 7.5 and stored at −20 °C and added
of 2 equiv of zinc before use. The peptide concentration was
determined on a UV−vis Spectrophotometer Lambda 20,
PerkinElmer, using an extinction coeﬃcient at 280 nm of 5700
M−1 cm−1.
Inhibition of NC-Mediated Destabilization of TAR and
cTAR Stem. The high throughput screening was performed to
identify inhibitors of NC chaperone activity on both TAR and
cTAR as previously described.21 We used a microplate reader
VictorIII (PerkinElmer) with 485 and 535 nm as excitation and
emission wavelengths. 5′-FAM and 3′-DAB modiﬁed TAR or
cTAR (each 1 μM) were folded in TNMg (10 mM Tris-HCl,
20 mM NaCl, 1 mM Mg(ClO4)2, pH 7.5): the oligonucleotides
were denatured at 95 °C for 5 min and then left to cool to
room temperature in order to assume their stem-bulge-loop
structure. cTAR or TAR was then diluted to 0.1 μM in TN (10
mM Tris-HCl, 20 mM NaCl pH 7.5). Increasing concen-
trations of compound (0, 0.1, 0.5, 1, 5, 10, 50, 100 μM ﬁnal)
were incubated with 0.1 μM cTAR or TAR in each well. Finally,
NC 0.8 μM (molar ratio oligos/NC = 1/8) was added to each
sample. The plate was read three times with a delay of 1 min
one reading from the other. The experimental data were ﬁtted
as reported and the IC50 value was calculated for each
compound.21 Each experiment was performed in triplicate to
calculate a standard deviation of the IC50 value.
Inhibition of TAR/cTAR Annealing by Anthraqui-
nones. Nucleocapsid annealing mediated electrophoresis
(NAME) assay was used to investigate the ability of
compounds to impair the biological activity of the full length
NC protein and of the truncated NC12−55 peptide, monitoring
the annealing of TAR with cTAR.23 TAR, cTAR, and the
hybrid TAR/cTAR (each 1 μM) each folded in TNMg (10
mM Tris-HCl, 20 mM NaCl, 1 mM Mg(ClO4)2 pH 7.5) were
used as controls: the oligonucleotides were denatured at 95 °C
for 5 min and then left to cool to room temperature in order to
assume their stem-bulge-loop (TAR and cTAR) or double-
stranded (hybrid TAR/cTAR) structure. To evaluate the
inhibition of NC- or NC12−55-mediated TAR/cTAR hybrid
formation, TAR (1 μM), and cTAR (1 μM) were folded
separately as described above, individually incubated with
increasing concentrations of compound (each oligo with 0, 1,
10, 50, 100 μM compound concentrations) for 15 min at room
temperature, mixed together, added to NC or NC12−55 solution
(8 μM, oligos/protein or oligos/peptide = 1/8) and then
incubated for other 15 min at room temperature. To the
samples were added Gel Loading Buﬀer containing SDS
(GLBSDS: 100 mM Tris-HCl, 4 mM EDTA, 50% w/v glycerol,
2% w/v SDS, 0.05% w/v bromophenol blue), held on ice, and
ﬁnally resolved on a 12% native PAGE (Acrylamide:Bis-
(acrylamide) = 19:1), run in TBE buﬀer (89 mM Tris, 89 mM
boric acid and 2 mM EDTA, pH 8) for 3 h at 200 V. After
electrophoresis, nucleic acids on the gel were stained with
SybrGreen II and detected on a Geliance 600 Imaging System
(PerkinElmer). The IC50 (concentration of the compound
required to inhibit the hybrid formation by half) was calculated
by the quantiﬁcation (using GeneTools software from
PerkinElmer) of the percentage of the hybrid formation.21
Inhibition of Tat/TAR Complex Formation by Anthra-
quinones. The eﬀect of peptidyl−anthraquinone conjugates
on the Tat/TAR complex was evaluated using a FRET-based
competition assay, as previously described.37,38 The peptide
sequence corresponding to the minimal amino acid sequence
(48−57; GRKKRRQRRR) necessary for TAR binding was
labeled with ﬂuorescein (FAM) at its N-terminus and the 29-nt
TAR was labeled at its 3′ end with a Dabcyl mojety (dark
quencher). Titrations of labeled Tat/TAR in the presence of
anthraquinones were made in triplicates in a 96-well plate
reader (Victor III, PerkinElmer); the FAM−labeled Tat was
excited at 490 nm and the emission was recorded at 535 nm.
The plates were assembled with 190 μL of a solution containing
10 nM FAM-peptide in TNMg (Tris 10 mM, pH 7.5,
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Mg(ClO4)2 1 mM, NaCl 20 mM, 0.01% Triton X-100), in the
presence of a ﬁxed amount of each compound (10 μM).
Fluorescence intensities in the presence of increasing
concentrations of Dabcyl-TAR were measured and curves
were ﬁtted to obtain Ki values. A preliminary determination of
the spectral parameters of all quinolones allowed us to exclude
optical interferences with ﬂuorescein-peptide signal at the
conditions of the assay.
TAR and cTAR Stabilization by Anthraquinones. The
ability of each compound to interact with the TAR and cTAR
structures was analyzed by ﬂuorescence quenching assay
(FQA), measuring the increase of melting temperature of the
oligonucleotide in the presence of anthraquinones. Each oligo
was folded at 10 μM in TNMg (10 mM Tris-HCl, 20 mM
NaCl, 1 mM Mg(ClO4)2 pH 7.5) and then diluted to 1 μM
concentration in ETN (1 mM EDTA, 10 mM Tris HCl, 20
mM NaCl, pH 7.5). In each microplate well the nucleic acid
solutions were mixed with the anthraquinone solution to the
ﬁnal concentration of 1 and 10 μM. Nucleic acid solutions
without compounds were used to measure the reference value
for Tm. The temperature was increased from 25 to 99 °C in 1 h
(0.02 °C/s) to promote the thermal denaturation of the
oligonucleotides, while the emission ﬂuorescence (at 510 nm)
was monitored (30 acquisitions per °C). The analysis was
performed using the LightCycler480 II (Roche). The Tm value
was mathematically derived from the thermal denaturing proﬁle
using LC480 software. ΔTm was calculated using the following
equation: ΔTm = Tm2·− Tm1, where Tm2 and Tm1 are the Tm
values measured testing the oligonucleotides in the presence
and in the absence of compound, respectively.
Identiﬁcation of Lysyl-Peptidyl-Anthraquinones Bind-
ing Sites on TAR. Enzymatic RNase footprinting was
employed to identify TAR regions involved in the binding of
anthraquinone conjugates. TAR was 5′-radioactively labeled
using T4 polynucleotide kinase (T4 PNK, Ambion, Applied
Biosystems, TX, USA) in the presence of [γ-32P] ATP (3000
Ci/mmol, PerkinElmer, MA, USA) following manufacturer’s
instructions. The analysis of TAR structure was performed both
in the absence and in the presence of 5 and the comparison of
the two diﬀerent patterns allowed the identiﬁcation of the TAR
regions involved in the binding. TAR structure analysis was
performed using 0.2 μg of TAR added of Structure Buﬀer (10
mM Tris pH 7, 0.1 M KCl, 10 mM MgCl2). TAR was then
denatured at 95 °C for 5 min and left to cool to room
temperature in order to assume its stem-bulge-loop structure.
To the samples was added 5 μL of compound (ﬁnal
concentration 300 μM) or DEPC-treated H2O. After 15 min
at room temperature, to the samples was added 2 μL of tRNA
(2 μg/μL) and ﬁnally to each sample tube was added a diﬀerent
RNase. RNA samples were digested with three sequential 10-
fold dilutions of each ribonuclease starting from RNase T1 1
U/μL (Ambion), RNase V1 0.1 U/μL (Ambion), and RNase A
1 μg/mL (Ambion). The samples not treated with RNases were
used as control. After 3 min incubation, the reactions were
stopped using 5 μL of denaturing Gel Loading Buﬀer (95%
formamide, 18 mM EDTA, 0.025% SDS, xylene cyanol and
bromophenol blue, from Ambion). The alkaline hydrolysis of
TAR was performed adding 1.5 μL of tRNA (2 μg/μL) to 0.1
μg of TAR in a ﬁnal volume of 15 μL in the Hydrolysis Buﬀer
(50 mM NaCO3, 1 mM EDTA, pH 9.2). Samples were heated
to 95 °C for 5 min and the reaction was stopped putting the
samples on ice and adding 5 μL of denaturing Gel Loading
Buﬀer (GLBD: 95% formamide, 18 mM EDTA, 0.025% SDS,
0.05% xylene cyanol and 0.05% bromophenol blue, from
Ambion). All samples were heated for 5 min at 95 °C, put on
ice, and ﬁnally resolved on a sequencing denaturing PAGE
(20% polyacrylamide gel with 7 M urea) for 1.5 h in TBE buﬀer
(89 mM Tris, 89 mM Boric acid, and 2 mM EDTA, pH 8) at
95 W. After the run, the gel was autoradiographed (with
Hyperﬁlm MP, Amersham ﬁlm, and intensifying screens,
Amersham) for 1 day and was then developed with developing
and ﬁxing buﬀers (Kodak).
Analysis of Peptidyl-Anthraquinones Binding to TAR.
TAR was folded in 150 mM ammonium acetate (pH 7.5)
containing 1 μM MgCl2: the oligonucleotide was denatured at
95 °C for 5 min and then left to cool to room temperature in
order to assume its stem-bulge-loop structure. Before mixing
with compounds, folded TAR was ﬁltered by using centrifugal
ﬁlters 3K NMWL (Millipore Corporation, MA, USA) to lower
the presence of magnesium salts that can adversely interfere
with ESI performance. Samples for the binding studies were
prepared by mixing appropriate volumes of folded TAR (1 μM
ﬁnal) with each compound in 150 mM ammonium acetate (pH
7.5). The ﬁnal mixtures contained up to a 10:1 lysyl-peptidyl-
anthraquinone/oligo molar ratio. To ensure the binding
equilibrium in solution, samples were incubated for 15 min at
room temperature before the analysis. Control experiments
were performed by using a solution of TAR (1 μM ﬁnal) in 150
mM ammonium acetate, and solutions of each compound (10
μM ﬁnal) in 150 mM ammonium acetate. All samples were
analyzed in negative ion mode by direct infusion electrospray
ionization (ESI) on a Thermo Fisher Scientiﬁc (West Palm
Beach, CA) LTQ-Orbitrap Velos mass spectrometer. The
analyses were performed in nanoﬂow ESI mode by using quartz
emitters produced in-house by a Sutter Instruments Co.
(Novato, CA) P2000 laser pipet puller. Up to 6 μL of sample
was loaded onto each emitter by using a gel loader pipet tip. A
stainless steel wire was inserted in the back-end of the emitter
and used to supply an ionizing voltage ranged around 0.8−1.0
kV. Source temperature and desolvation conditions were
adjusted to decrease the incidence of salt adducts, with typical
source temperature of 200 °C. Data were processed by using
Xcalibur 2.1 software (Thermo Scientiﬁc).
Analysis of 1, 5, and 6 Lysyl-Peptidyl-Anthraquinones
Binding to NC. Samples for the binding studies were prepared
by mixing appropriate volumes of stock solution of the full
length NC (2 μM ﬁnal) with each compound in 150 mM
ammonium acetate (pH 7.5). The ﬁnal mixtures contained up
to a 20:1 compound/NC molar ratio, which allowed the
detection of anthraquinones binding to the protein. In order to
ensure the binding equilibrium in solution before analysis, the
samples were incubated for 15 min at room temperature. We
performed control experiments using a solution of NC protein
in 150 mM ammonium. All samples were analyzed in positive
ion mode by direct infusion electrospray ionization (ESI) on a
Thermo Fisher Scientiﬁc (West Palm Beach, CA) LTQ-
Orbitrap Velos mass spectrometer. The analyses were
performed as previously described for the ESI-MS binding
analysis of lysyl-peptidyl-anthraquinones to TAR.
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M., Van Dorsselaer, A., Meĺy, Y., and de Rocquigny, H. (2009)
Identification by high throughput screening of small compounds
inhibiting the nucleic acid destabilization activity of the HIV-1
nucleocapsid protein. Biochimie 91, 916−923.
(26) Sosic, A., Cappellini, M., Sinigaglia, L., Jacquet, R., Deffieux, D.,
Fabris, D., Quideau, S., and Gatto, B. (2015) Polyphenolic C-
Bioconjugate Chemistry Article
DOI: 10.1021/acs.bioconjchem.5b00627
Bioconjugate Chem. 2016, 27, 247−256
255
glucosidic ellagitannins present in oak-aged wine inhibit HIV-1
nucleocapsid protein. Tetrahedron 71, 3020−3026.
(27) Beltz, H., Piemont, E., Schaub, E., Ficheux, D., Roques, B.,
Darlix, J. L., and Mely, Y. (2004) Role of the structure of the top half
of HIV-1 cTAR DNA on the nucleic acid destabilizing activity of the
nucleocapsid protein NCp7. J. Mol. Biol. 338, 711−23.
(28) Kanevsky, I., Chaminade, F., Chen, Y., Godet, J., Rene, B.,
Darlix, J. L., Mely, Y., Mauffret, O., and Fosse, P. (2011) Structural
determinants of TAR RNA-DNA annealing in the absence and
presence of HIV-1 nucleocapsid protein. Nucleic Acids Res. 39, 8148−
62.
(29) Boudier, C., Storchak, R., Sharma, K. K., Didier, P., Follenius-
Wund, A., Muller, S., Darlix, J. L., and Mely, Y. (2010) The mechanism
of HIV-1 Tat-directed nucleic acid annealing supports its role in
reverse transcription. J. Mol. Biol. 400, 487−501.
(30) Boudier, C., Humbert, N., Chaminade, F., Chen, Y., de
Rocquigny, H., Godet, J., Mauffret, O., Fosse, P., and Mely, Y. (2014)
Dynamic interactions of the HIV-1 Tat with nucleic acids are critical
for Tat activity in reverse transcription. Nucleic Acids Res. 42, 1065−78.
(31) Nabel, G., and Baltimore, D. (1987) An inducible transcription
factor activates expression of human immunodeficiency virus in T
cells. Nature 326, 711−3.
(32) Berkhout, B., Silverman, R. H., and Jeang, K. T. (1989) Tat
trans-activates the human immunodeficiency virus through a nascent
RNA target. Cell 59, 273−82.
(33) Weeks, K. M., Ampe, C., Schltz, S. C., Steitz, T. A., and
Crothers, D. M. (1990) Fragments of the HIV-1 Tat protein
specifically bind TAR RNA. Science 249, 1281−1285.
(34) Rana, T. M., and Jeang, K. T. (1999) Biochemical and functional
interactions between HIV-1 Tat protein and TAR RNA. Arch. Biochem.
Biophys. 365, 175−85.
(35) Churcher, M. J., Lamont, C., Hamy, F., Dingwall, C., Green, S.
M., Lowe, A. D., Butler, J. G., Gait, M. J., and Karn, J. (1993) High
affinity binding of TAR RNA by the human immunodeficiency virus
type-1 tat protein requires base-pairs in the RNA stem and amino acid
residues flanking the basic region. J. Mol. Biol. 230, 90−110.
(36) Cao, H., Tamilarasu, N., and Rana, T. M. (2006) Orientation
and affinity of HIV-1 Tat fragments in Tat-TAR complex determined
by fluorescence resonance energy transfer. Bioconjugate Chem. 17,
352−8.
(37) Manfroni, G., Gatto, B., Tabarrini, O., Sabatini, S., Cecchetti, V.,
Giaretta, G., Parolin, C., del Vecchio, C., Calistri, A., Palumbo, M.,
et al. (2009) Synthesis and Biological Evaluation of 2-Phenyl-
quinolones Targeted at Tat/TAR Recognition. Bioorg. Med. Chem.
Lett. 19, 714−717.
(38) Tabarrini, O., Massari, S., Daelemans, D., Meschini, F.,
Manfroni, G., Bottega, L., Gatto, B., Palumbo, M., Pannecouque, C.,
and Cecchetti, V. (2010) Studies of anti-HIV transcription inhibitor
quinolones: identification of potent N1-vinyl derivatives. ChemMed-
Chem 5, 1880−92.
(39) Gooch, B. D., and Beal, P. A. (2004) Recognition of duplex
RNA by helix-threading peptides. J. Am. Chem. Soc. 126, 10603−10.
(40) Scalabrin, M., Siu, Y., Asare-Okai, P. N., and Fabris, D. (2014)
Structure-specific ribonucleases for MS-based elucidation of higher-
order RNA structure. J. Am. Soc. Mass Spectrom. 25, 1136−45.
(41) McCauley, M. J., Rouzina, I., Manthei, K. A., Gorelick, R. J.,
Musier-Forsyth, K., and Williams, M. C. (2015) Targeted binding of
nucleocapsid protein transforms the folding landscape of HIV-1 TAR
RNA. Proc. Natl. Acad. Sci. U. S. A. 112, 13555−60.
(42) Rye, H. S., and Glazer, A. N. (1995) Interaction of dimeric
intercalating dyes with single-stranded DNA. Nucleic Acids Res. 23,
1215−22.
(43) Wang, Z., and Rana, T. M. (1996) RNA conformation in the
Tat-TAR complex determined by site-specific photo-cross-linking.
Biochemistry 35, 6491−9.
(44) Wang, Z., and Rana, T. M. (1998) RNA-protein interactions in
the Tat-trans-activation response element complex determined by site-
specific photo-cross-linking. Biochemistry 37, 4235−43.
(45) Turner, K. B., Hagan, N. A., and Fabris, D. (2006) Inhibitory
effects of archetypical nucleic acid ligands on the interactions of HIV-1
nucleocapsid protein with elements of Psi-RNA. Nucleic Acids Res. 34,
1305−16.
(46) Turner, K. B., Hagan, N. A., Kohlway, A. S., and Fabris, D.
(2006) Mapping noncovalent ligand binding to stemloop domains of
the HIV-1 packaging signal by tandem mass spectrometry. J. Am. Soc.
Mass Spectrom. 17, 1402−11.
(47) Turner, K. B., Kohlway, A. S., Hagan, N. A., and Fabris, D.
(2009) Noncovalent probes for the investigation of structure and
dynamics of protein-nucleic acid assemblies: the case of NC-mediated
dimerization of genomic RNA in HIV-1. Biopolymers 91, 283−96.
(48) Hagan, N., and Fabris, D. (2003) Direct mass spectrometric
determination of the stoichiometry and binding affinity of the
complexes between nucleocapsid protein and RNA stem-loop hairpins
of the HIV-1 Psi-recognition element. Biochemistry 42, 10736−45.
(49) Fabris, D., Zaia, J., Hathout, Y., and Fenselau, C. (1996)
Retention of Thiol Protons in Two Classes of Protein Zinc Ion
Coordination Centers. J. Am. Chem. Soc. 118, 12242−12243.
Bioconjugate Chemistry Article
DOI: 10.1021/acs.bioconjchem.5b00627
Bioconjugate Chem. 2016, 27, 247−256
256
